Home › Companies › UNCY

Unicycive Therapeutics

Market cap $108M 29.2M shares (10-Q, Nov 16, 2026) × $3.70 close Nov 17, 2026

Most recent annual filing: 2026-03-30

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. UNCY TDAPA corporate updateDec 31, 2026UNCY TDAPA corporate update, Dec 31, 2026, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

Capital (as filed)

Cash
$42.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$17.0M Sep 30, 2026
Operating cash flow
−$7.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$59.0M cash, runway beyond 2027 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (6)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (6 calls)

Every verdict Biotech Distilled has published on Unicycive Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Unicycive Therapeutics (UNCY) - Scientific Deep Dive for Oxylanthanum Carbonate (OLC) and Pipeline Products OLC is a legitimate, approvable reformulation but buying common four days before a manufacturing-driven PDUFA at a 52-week high with heavy dilution and an unresolved CMS TDAPA thesis is poor risk/reward; revisit after the binary and reimbursement question de-risk.
  2. Avoid UPDATE: Unicycive Therapeutics (UNCY) — The Same CRL, Twice A second CRL on the same manufacturing deficiency with the FDA never having inspected the site, combined with the class-wide TDAPA window expiring December 31 2026 and post-approval financing now coming from a position of weakness, makes the commercial thesis structurally degraded.
  3. Avoid UPDATE: Unicycive Therapeutics (UNCY) - The Inspection Finally Got Assigned An assigned inspection converts the gating item from unschedulable to dated and binary, but the vendor has failed to clear cGMP across two review cycles, dilution is realized and permanent, and the reimbursement window keeps shrinking; the inspection result, not the assignment, is the event worth waiting for.
  4. Watch UPDATE: Unicycive Therapeutics (UNCY) - They Stopped Waiting for the Factory Resubmission with a new vendor carrying a clean NAI inspection record and a dated PDUFA around late March 2027 removes the main reason for AVOID, but TDAPA eligibility remains unconfirmed, the class-wide window closes before any realistic approval, and ATM dilution continues below warrant strikes.
  5. Watch UPDATE: Unicycive Therapeutics (UNCY) - The Clock Is Set: March 25, 2027 FDA acceptance as Class II with a March 25 2027 PDUFA confirms the timeline, but a possible pre-approval inspection of the new site is unresolved, TDAPA eligibility is unconfirmed, and the stock trades well below every warrant strike with an active ATM overhead.
  6. Watch UPDATE: Unicycive Therapeutics (UNCY) - CMS Finally Spoke CMS's 2027 rule narrows the TDAPA question to a single FDA NDA classification decision at approval, the original vendor has finally been inspected, and the PDUFA remains March 25 2027, but approval odds in the company's own model keep falling, ATM dilution continues below warrant strikes, and a second securities class action has been filed.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (26)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)